StockData
Denali Therapeutics Inc. logo

Denali Therapeutics Inc. (DNLI) stock

DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30
$18.40+0.40 (+2.22%)

Close on Nov 18, 2026Market cap $2.94BP/E –Yield –

Denali Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.51M–
Q2 FY2025Jun 30, 2025$0–

More Denali Therapeutics figures

See a number that looks wrong?